Cadila Healthcare has informed that it has enclosed a copy of press release dated May 29, 2021 titled ‘Zydus Cadila receives final approval from USFDA for Fluphenazine Hydrochloride Tablets’. Bring this news to the notice of the members of the exchange and the investors’ at large.
The above information is a part of company’s filings submitted to BSE.